Twelve Organizations Collaborate to Advance CGT Industry at the 10th CGT Park Tour Stop in Bin'ao Building, Hangzhou

This event received strong support from the Development Service Center of Hangzhou High-Tech Zone (Binjiang) Zero-Magnetic Science Valley (Smart New World).Pan Jie, Member of the Party Committee and Deputy Director of Zero Magnetic Valley (Xintiandi) CenterIntroduction: The Zero-Magnetic Science Valley (Smart New World), covering an area of approximately 7.6 square kilometers, is composed of the International Zero-Magnetic Science Valley and the Smart New World. It serves as the primary hub for the clustered development of the life and health industry, and stands as a key vehicle for the High-Tech Zone (Binjiang) to create a “second breakthrough point” following the digital economy, thereby fostering another trillion-yuan industrial cluster. The area encompasses “One Valley and One Town,” namely the International Zero-Magnetic Science Valley and the Binjiang Digital Health Town. The International Zero-Magnetic Science Valley centers on ultra-high-sensitivity ultra-weak magnetic field and inertial measurement devices, along with five interdisciplinary research platforms, prioritizing the development of three major industries: zero-magnetic medicine, quantum information, and artificial intelligence. The Binjiang Digital Health Town focuses on internet healthcare, medical big data, and medical AI, accelerating the deep integration of “BT+IT+AI” and emphasizing the “1+2” industrial model—centered on smart healthcare, and featuring high-end medical devices and innovative drugs. Through the synergistic development of the “Valley” and the “Town,” the area is committed to building a “new center for green development, a new highland for digital health, and a new model for future cities.”

He stated that cell and gene therapy (CGT), as an emerging frontier in the biotechnology sector, is leading the key development trends in the life sciences for the next decade. The Zero Magnetic Valley (Xintiandi) Center aims to leverage the developmental advantages of the Binjiang District Biopharmaceutical Industrial Park, uphold the service philosophy of “speaking the truth and taking practical action,” and better serve enterprises and industrial growth through the latest industrial policies and resources.

▲ Pan Jie | Member of the Party Committee and Deputy Director of the Zero Magnetic Valley (Xintiandi) Center

Ms. Cai Rongrong, Business Director of Jintou Times, introducing the locational advantages and functional layout of the Hangzhou High-Tech Zone (Binjiang) Biopharmaceutical Industrial Park. The park aims to develop a “1+2” industrial framework centered on smart healthcare, with high-end medical devices and innovative drug R&D as its distinctive pillars, while accelerating the development of new quality productive forces to build an industrial hub characterized by collaborative innovation and integration among scientists, entrepreneurs, and investors.

Currently, Bei’ao Building has established an integrated operational service system featuring a tripartite model of “District Government + State-Owned Capital Platform + Operations Team,” delivering comprehensive and professional industrial operation services spanning technological innovation, talent development, industry support, and finance. Under this framework, the District Government oversees overall planning and layout; Hangzhou High-Tech Jintou Holding Group Co., Ltd., as the state-owned capital platform, leads overall investment and construction to empower the commercialization of scientific and technological achievements and foster the growth of high-tech industries; and Hangzhou Jintou Times Enterprise Management Co., Ltd. (“Jintou Times”), serving as the operations team, leverages the flexibility of market-oriented mechanisms to organically integrate government planning, state-owned construction, and market-driven operations, thereby achieving a synergistic effect where “1+1+1>3.”

The Hangzhou High-Tech Industrial Development Zone (Binjiang) Biomedical Innovation Alliance (BIA) is an open, non-profit collaborative organization jointly initiated by leaders of multiple innovative pharmaceutical companies within the zone, targeting all innovative enterprises in the biomedical industry. With technological innovation as its core and service to member organizations as its mission, BIA leverages established experts and enterprises in innovative drugs, in vitro diagnostics, and high-end medical devices within the zone to identify promising innovative biomedical companies. By integrating research institutions, hospitals, contract research organizations (CROs), professional investment firms, and government agencies, BIA fosters a comprehensive biomedical industrial ecosystem. This initiative aims to promote the development of the innovative biomedical sector in the High-Tech Zone (Binjiang) and facilitate the public listing of more biomedical companies. To date, the alliance has grown to include 119 member enterprises and institutions.

Finally, she expressed her welcome for more industrial partners to settle in the Hangzhou High-Tech Zone (Binjiang) Biomedical Industrial Park, so as to facilitate more exchanges and cooperation opportunities and jointly promote the development of the industry.

▲Cai Rongrong | Commercial Director, Golden Investment Era

During the flash presentation session on the core values of supply chain enterprises, five vendor companies and Shanghai Pudong Development Bank’s Hangzhou Branch respectively showcased their unique core values and innovative solutions.

Company 1: Xingcheng Bio

▲ Li Junhui | Vice President of Science, Technology and Production at Xingcheng Biologics

Xingcheng Bio is a professional gene and cell therapy CDMO integrating plasmid and viral vector production, mRNA manufacturing, and analytical testing. The company has successful experience in filing Investigational New Drug (IND) applications for plasmids and viral vectors in both China and the United States, achieving zero deficiency letters. It provides customized services including process development, cGMP manufacturing, analytical method development, and product release testing for plasmids, viral vectors, and mRNA.

The company was co-founded by senior CMC experts with commercialization experience in the gene and cell therapy sector, alongside accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations. Equipped with advanced production and analytical instrumentation, our team possesses extensive process development capabilities and practical expertise. Guided by the philosophy of “Sincerity in Action,” we leverage robust processes that exceed industry standards to provide partners with high-purity, high-yield, and cost-effective services for the preparation of plasmids, viral vectors, and mRNA at various production scales, from R&D to GMP grade.

Company 2: Yeasen Biotechnology

▲Tan Guosheng | Director of Key Accounts, Yeasen Biotechnology

Yeasen Biotechnology is a high-tech enterprise focused on core raw materials in the upstream segment of the life science industry chain, engaged in the research and development, production, and sales of biological reagents across three major categories: molecular, protein, and cellular. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen Biotechnology has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity.

The Company develops, manufactures, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various categories of biological reagents. Its core product portfolio spans multiple categories, including qPCR series, NGS series, reverse transcription series, nucleic acid extraction and purification series, PCR series, molecular cloning series, in vitro transcription series, antibodies, protein purification series, protein analysis series, recombinant proteins, cell analysis series, cell culture series, cell transfection series, and reporter gene detection series. These products are widely applied in fields such as life science research, diagnostic testing, and biopharmaceuticals.

Company 3: Lepu Biopharma

▲ Xiong Yi | Application Director of Cell Culture Products at Lepu Biotech

LePure Biotech, founded in 2011, has integrated outstanding brands such as Geshi Fluidics, Kangsheng Biotechnology, and Stanleys through an external growth strategy. Its business now covers multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination-controlled clean solutions. It has become a widely recognized leading supplier providing end-to-end upstream biopharmaceutical processing solutions.

Enterprise 4: Shenyan Bio

▲ Chen Lin | Director of Business Development, Deep Research Biotech

Shenyan Biotech, established in 2014, is a core upstream supplier in the field of cell and gene therapy (CGT), providing leading technical services and production tools for CGT enterprises, including viral vector production solutions and comprehensive solutions for cell-based drug manufacturing.

In the realm of viral vector production solutions, EuBiologics has designed and implemented its proprietary EuBioX automated laboratory system. By integrating advanced technologies such as big data analytics, bioinformatics, and automation, the company has innovatively developed the EuLV® system for large-scale lentiviral vector production using stable producer cell lines. This breakthrough addresses technical bottlenecks in scaling up lentiviral vector manufacturing, leveraging globally leading technology to significantly enhance production efficiency and product consistency while substantially reducing production costs.

Meanwhile, as a leading enterprise in automated cell preparation equipment in China, Shenyan Biology has independently developed the CellSep® series of cell processing systems, which are suitable for the standardized production of various cell-based therapies. The company has also launched equipment such as sterile tube welders, heat sealers, and wave bioreactors, providing an integrated automation solution for cell therapy manufacturing and comprehensively enhancing production efficiency.

Company Five: Anshengda

▲ Zhou Qiankai | Anshengda NGS Application Scientist

Azenta is a global provider of automated solutions for pharmaceutical R&D, sample storage, and management. Azenta is dedicated to helping life science organizations worldwide bring breakthrough research findings and therapies to market faster. Through its exceptional sample research and management solutions, it helps customers accelerate discovery, R&D, and delivery.

Currently, Anshengda employs over 3,000 people worldwide, with its business spanning six major product categories across North America, Europe, and Asia. Leveraging years of specialized expertise accumulated in genomics, cryogenic storage, automation, and informatics, the company provides customers with end-to-end sample research and management solutions covering the entire drug development lifecycle.

▲ Chen Ke | General Manager, Technology Finance Department, SPDB Hangzhou Branch

SPD Bank has positioned tech finance as its “top priority,” establishing a “5+7+X” product suite and an integrated service ecosystem encompassing equity, debt, lending, insurance, leasing, incubation, matchmaking, and collaboration. By leveraging digital intelligence capabilities and focusing resources, the bank is committed to building its market brand and position as the “preferred banking partner for technology enterprises.”

As of the end of 2023, Shanghai Pudong Development Bank’s Hangzhou Branch served over 4,500 technology-based enterprises, with an outstanding balance of technology loans exceeding RMB 50 billion. This demonstrates its remarkable achievements in tech finance and its positive contribution to local economic development.

Panel 1 Session byDr. Liu XiaoHost, Guest SpeakersXu Kai, Founder of Nuoen Biotech; Li Zhaozhong, Co-founder and CTO of NurunJie; Li Junhui, Vice President of Production at Xingcheng Biotechnology; Tan Guosheng, Key Account Director at Yeasen Biotechnology; Xiong Yi, Application Director for Cell Culture Products at Lepu Biotech; Chen Lin, Business Development Director at Shenyan BiotechShared diverse perspectives and in-depth insights on the topic “How Can Party A and Party B Interact Constructively and Join Forces to Weather the Storm During Extraordinary Times?”

Guest Insights:The relationship between Party A and Party B is one of cooperative mutual trust, respect, and support, rather than an adversarial or zero-sum dynamic. As Party A, you should extend sufficient patience and tolerance to Party B. When issues arise, take the initiative to step in and resolve them, working collaboratively with Party B to refine solutions. Furthermore, when risks are manageable, Party A should have the courage to be a pioneer by adopting differentiated innovative services provided by Party B, thereby potentially achieving rapid advancement and surpassing competitors.

As the service provider, one must first possess robust technical capabilities, including stable and mature process technologies, a compliant quality management system, and full regulatory compliance, thereby striving to help the client avoid potential pitfalls. “Demanding clients are good clients.” Given the client’s exceptionally high expectations for technical services, the service provider must demonstrate even greater professionalism than the client. This also requires the service provider to intensify efforts in technological innovation, continuously explore innovative solutions, and enhance both service efficiency and quality.

Drug development in the field of cell and gene therapy (CGT) is a protracted process that requires joint efforts from both the sponsor and the contract organization. By leveraging complementary resources, they can collectively address the risks and challenges inherent in drug development, ultimately advancing the commercialization of candidate drugs.

▲Panel 1—Extraordinary Times,

How Can Party A and Party B Engage in Positive Interaction and Join Forces for Mutual Support?

Guest Insights:Amid a cooling market and shifting investment landscape, the entire industry must innovate and rebuild confidence. As the source of innovation in the cell and gene therapy (CGT) sector, researchers should conduct their studies based on market and clinical needs. When translating innovative research into commercial products, scientists must step out of their comfort zones, reshape their business mindset, and clarify the underlying logic of commercial translation, thereby successfully closing the loop from scientific research to commercialization.

Beyond this, while financing is a crucial source of funding for startups, it is not the only one. During downturns in the capital market, scientist-founders and startups can secure funds through multiple channels, with banks being one of them. Startups should strive to establish partnerships with banks, selecting the most suitable solutions based on their development needs and financial planning to help them “survive” in challenging environments.

Meanwhile, investment firms, banks, and other financial institutions are actively seeking change by launching a variety of services and solutions to help companies expand overseas and navigate challenging economic cycles, ultimately driving the industry forward.

▲Panel 2—Under the New Situation,

How Can CGT Companies Effectively “Raise Capital and Engage in Business Development”?

At this point,“[No Need to Compete Fiercely, Go Further] CGT Industry Upgrade Series · Park Tour Stop 10”Successfully Concluded! The event facilitated greater interconnectivity, resource sharing, and in-depth collaboration among enterprises. VCBeat New Medicine will continue to collaborate with industry chain partners to host a series of events. Please stay tuned. We look forward to seeing you again at future events as we work together to go further!

 ▲Group Photo of Guests